Clinical trials: Stage III Bladder Cancer AJCC v8
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Conditions
- Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Trial name
- NCT00118040
- Testing
- Genistein, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy (RT) uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055601
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- Radiation Therapy Oncology Group
Stage I Bladder Cancer, Stage II Bladder Cancer
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer
Green tea extract contains ingredients that may slow the growth of certain cancers. It is not yet known whether green tea extract is more effective than a placebo when given before surgery in treating patients with bladder.
- Conditions
- Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Trial name
- NCT00666562
- Testing
- Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Distal Urethral Cancer, Proximal Urethral Cancer
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their…
- Conditions
- Distal Urethral Cancer, Proximal Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage II Bladder Cancer
- Trial name
- NCT01611662
- Testing
- gemcitabine hydrochloride, cisplatin, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Recurrent Bladder Cancer, Stage III Bladder Cancer
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery.
- Conditions
- Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT01382706
- Testing
- docetaxel, lapatinib ditosylate, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back.
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma
- Trial name
- NCT00749892
- Testing
- Erlotinib Hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00112671
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Bladder, Distal Urethral Cancer
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium.
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer
- Trial name
- NCT00112905
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Bladder Cancer, Stage IV Bladder Cancer
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
This randomized phase II trial studies the side effects and how well postoperative intensity modulated radiotherapy works after surgery in treating patients with urothelial bladder cancer.
- Trial name
- NCT02316548
- Testing
- Intensity-Modulated Radiation Therapy
- Where
- 127 sites in United States, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- NRG Oncology
Recurrent Bladder Carcinoma, Stage II Bladder Cancer
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
This phase I/II trial studies the side effects and best dose of sirolimus when given together with cisplatin and gemcitabine hydrochloride and to see how well they work in treating patients with bladder cancer.
- Conditions
- Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
- Trial name
- NCT01938573
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Washington
Bladder Cancer
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00089128
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Bladder Cancer
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00526656
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Bladder Cancer
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer.
- Trial name
- NCT01224665
- Testing
- therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy
- Where
- 35 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00777491
- Testing
- induction cisplatin, induction 5-fluorouracil, induction gemcitabine
- Where
- 11 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Radiation Therapy Oncology Group
Bladder Cancer
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268450
- Testing
- bevacizumab, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT03513952
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer.
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT05581589
- Testing
- Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington